Department of Gynecologic Oncology, Health Science University, Cam Sakura Training and Research Hospital, Istanbul, Turkey.
Obstetrics and Gynecology Unit, Department of General Surgery and Medical Surgical Specialties, University of Catania, Via Santa Sofia 78, 95123, Catania, Italy.
Arch Gynecol Obstet. 2022 Dec;306(6):2105-2114. doi: 10.1007/s00404-022-06563-8. Epub 2022 Apr 24.
This study aimed to evaluate trefoil factor 3 (TFF3), secreted frizzled-related protein 4 (sFRP4), reactive oxygen species modulator 1 (Romo1) and nuclear factor kappa B (NF-κB) as diagnostic and prognostic markers of endometrial cancer (EC) and ovarian cancer (OC).
Thirty-one patients with EC and 30 patients with OC undergone surgical treatment were enrolled together with 30 healthy controls in a prospective study. Commercial ELISA kits determined serum TFF-3, Romo-1, NF-кB and sFRP-4 concentrations.
Serum TFF-3, Romo-1 and NF-кB levels were significantly higher in patients with EC and OC than those without cancer. Regarding EC, none of the serum biomarkers differs significantly between endometrial and non-endometrioid endometrial carcinomas. Mean serum TFF-3 and NF-кB levels were significantly higher in advanced stages. Increased serum levels of TFF-3 and NF-кB were found in those with a higher grade of the disease. Regarding OC, none of the serum biomarkers differed significantly among histological subtypes. Significantly increased serum levels of NF-кB were observed in patients with advanced-stage OC than those with stage I and II diseases. No difference in serum biomarker levels was found between those who had a recurrence and those who had not. The sensibility and specificity of these four biomarkers in discriminating EC and OC from the control group showed encouraging values, although no one reached 70%.
TFF-3, Romo-1, NF-кB and SFRP4 could represent new diagnostic and prognostic markers for OC and EC. Further studies are needed to validate our results.
本研究旨在评估三叶因子 3（TFF3）、卷曲相关蛋白 4（sFRP4）、活性氧调节剂 1（Romo1）和核因子 kappa B（NF-κB）作为子宫内膜癌（EC）和卵巢癌（OC）的诊断和预后标志物。
前瞻性研究纳入了 31 例接受手术治疗的 EC 患者和 30 例 OC 患者，以及 30 名健康对照者。采用商业 ELISA 试剂盒测定血清 TFF-3、Romo-1、NF-кB 和 sFRP-4 浓度。
EC 和 OC 患者的血清 TFF-3、Romo-1 和 NF-кB 水平明显高于无癌症患者。对于 EC，子宫内膜和非子宫内膜样子宫内膜癌患者的血清生物标志物无显著差异。晚期患者的血清 TFF-3 和 NF-кB 水平明显升高。疾病分级较高的患者血清 TFF-3 和 NF-кB 水平升高。OC 患者的组织学亚型之间，无任何血清生物标志物存在显著差异。与 I 期和 II 期疾病患者相比，晚期 OC 患者的血清 NF-кB 水平显著升高。在复发患者和未复发患者之间，血清生物标志物水平无差异。这四种生物标志物在区分 EC 和 OC 与对照组方面具有令人鼓舞的诊断价值，尽管没有一种标志物的灵敏度和特异性达到 70%。
TFF3、Romo1、NF-кB 和 SFRP4 可能成为 OC 和 EC 的新的诊断和预后标志物。需要进一步的研究来验证我们的结果。
